Alpha Crest Capital Management LLC Revance Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $77,353 - $153,681	-5,398 Reduced 23.43%	17,642 $476,000
Q2 2022 Aug 11, 2022	BUY	$11.52 - $20.4 $265,420 - $470,015	23,040 New	23,040 $318,000
Q1 2022 May 12, 2022	SELL	$12.36 - $20.31 $431,487 - $709,022	-34,910 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$12.46 - $27.87 $434,978 - $972,941	34,910 New	34,910 $570,000
Q3 2021 Nov 10, 2021	SELL	$25.78 - $33.21 $456,306 - $587,817	-17,700 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$24.03 - $29.97 $151,389 - $188,811	-6,300 Reduced 26.25%	17,700 $495,000
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $301,989 - $365,586	12,900 Added 116.22%	24,000 $680,000
Q3 2020 Nov 12, 2020	BUY	$23.23 - $34.3 $257,853 - $380,729	11,100 New	11,100 $279,000
Q3 2019 Nov 12, 2019	SELL	$10.22 - $14.5 $179,872 - $255,200	-17,600 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$10.67 - $15.49 $60,819 - $88,293	5,700 Added 47.9%	17,600 $228,000
Q1 2019 May 10, 2019	BUY	$15.4 - $20.39 $183,260 - $242,641	11,900 New	11,900 $188,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.